Marimed Inc
OTC:MRMD

Watchlist Manager
Marimed Inc Logo
Marimed Inc
OTC:MRMD
Watchlist
Price: 0.09 USD -4.26% Market Closed
Market Cap: 35.6m USD

Relative Value

The Relative Value of one MRMD stock under the Base Case scenario is 0.5 USD. Compared to the current market price of 0.09 USD, Marimed Inc is Undervalued by 82%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRMD Relative Value
Base Case
0.5 USD
Undervaluation 82%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
89
Median 3Y
0.5
Median 5Y
1
Industry
2.6
Forward
0.2
vs History
vs Industry
40
Median 3Y
-3.5
Median 5Y
10.6
Industry
21.4
Forward
-2.9
vs History
52
vs Industry
46
Median 3Y
9.6
Median 5Y
9.9
Industry
16.4
vs History
vs Industry
5
Median 3Y
-1.8
Median 5Y
-1.7
Industry
22.8
vs History
88
vs Industry
75
Median 3Y
0.9
Median 5Y
1.4
Industry
2.2
vs History
90
vs Industry
80
Median 3Y
0.9
Median 5Y
1.2
Industry
2.9
Forward
0.6
vs History
85
vs Industry
75
Median 3Y
2.1
Median 5Y
2.6
Industry
5.5
vs History
34
vs Industry
40
Median 3Y
7.3
Median 5Y
7.8
Industry
13
Forward
5.6
vs History
11
vs Industry
17
Median 3Y
14.2
Median 5Y
11.4
Industry
16.5
Forward
25.5
vs History
22
vs Industry
27
Median 3Y
19.9
Median 5Y
15.9
Industry
15.6
vs History
7
vs Industry
Median 3Y
-18.4
Median 5Y
-14.4
Industry
18.7
vs History
92
vs Industry
73
Median 3Y
0.7
Median 5Y
1.1
Industry
1.9

Multiples Across Competitors

MRMD Competitors Multiples
Marimed Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Marimed Inc
OTC:MRMD
35.5m USD 0.2 -2 8 99.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
259.1B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP 4.8 30 108.3 158.5
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
CH
Novartis AG
SIX:NOVN
207.2B CHF 4.7 18.2 11.5 14.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.8 14.5 10.1 11.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
US
Marimed Inc
OTC:MRMD
Average P/E: 24.2
Negative Multiple: -2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
37%
0.8
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
3%
4.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Marimed Inc
OTC:MRMD
Average EV/EBITDA: 400.5
8
21%
0.4
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
1%
10.1
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Marimed Inc
OTC:MRMD
Average EV/EBIT: 1 721.1
99.4
58%
1.7
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5